A phenylpiperidine compound and a use thereof. The phenylpiperidine compound is a compound represented by formula (0), or a stereoisomer, a tautomer, a nitrogen oxide, a solvate, a metabolite, a prodrug, or a pharmaceutically acceptable salt or ester thereof. Also provided is a use of the phenylpiperidine compound in preparation of drugs for treating ophthalmic diseases.
A61K 31/451 - Non-condensed piperidines, e.g. piperocaine having a carbocyclic ring directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
Disclosed in the present invention is a compound as shown in formula (I), or a stereoisomer, tautomer, nitrogen oxide, solvate, metabolite and prodrug thereof, or a pharmaceutically acceptable salt or ester thereof. Further disclosed in the present invention is the use of the compound in the preparation of a drug for treating ophthalmic diseases.
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
The present invention provides use of a steroid compound in preparing drugs for preventing and/or treating presbyopia. The steroid compound provided by the present invention is represented by formula (I). The steroid compound has the effect of treating, alleviating and preventing presbyopia, and can greatly alleviate and/or cure presbyopia to improve vision.
The present invention provides use of a steroid compound in preparing drugs for preventing and/or treating presbyopia. The steroid compound provided by the present invention is represented by formula (I). The steroid compound has the effect of treating, alleviating and preventing presbyopia, and can greatly alleviate and/or cure presbyopia to improve vision.
A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A pharmaceutical composition, a preparation method therefor and an application thereof. The pharmaceutical composition comprises the following components: a compound represented by formula I, hydroxypropyl methyl cellulose, benzalkonium chloride, and a pH regulator. The pharmaceutical composition can be used for preparing drugs for preventing or treating cataracts. The pharmaceutical composition has excellent stability in respect of exposure to light and to high temperatures, can be stored at room temperature, is convenient for patients to use, has pH and osmotic pressure close to those in the intraocular environment, is uniform in particle size distribution, and thus can give the patients good comfort.
A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
Provided are a steroid compound and a pharmaceutical composition comprising the steroid compound. The steroid compound has a structure as shown in formula (I), or a stereoisomer, a tautomer, a nitrogen oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug of the structure shown in formula (I). The compound or composition can be used for preparing drugs for preventing, dealing with, treating or alleviating eye diseases of patients.
An application of a steroid compound in the preparation of a drug for preventing and/or treating eye floaters. The steroid compound can have good therapeutic, alleviative, and preventive effects on eye floaters, can alleviate and/or cure eye floaters to a great extent, and can improve visual clarity.
A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
A steroidal compound, a preparation method therefor and an application thereof. On one hand, provided are a compound represented by formula I, a preparation method therefor, and an application thereof in a method for separating and purifying lanosterol; on the other hand, provided is the method for separating and purifying lanosterol. The method is simple to operate, stable in process, high in productivity and low in cost, and the obtained lanosterol has high purity and can meet medical application thereof.
C07J 9/00 - Normal steroids containing carbon, hydrogen, halogen, or oxygen, substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
A composition containing loxoprofen sodium. The composition comprises loxoprofen sodium, sodium hyaluronate and polysorbate 80, wherein the molecular weight of sodium hyaluronate is 0.8×106−1.6×106. The composition has good stability and a long shelf life and is convenient to use.
The present invention relates to an application of loxoprofen sodium or a composition containing loxoprofen sodium in the preparation of a drug for preventing and/or treating the dry eye disease.
The present invention provides use of a steroid compound in the preparation of a medicament for preventing and/or treating myopia. The steroid compound provided in the present invention is represented by formula (I), has the effects of treating, relieving and preventing myopia, and can greatly delay, improve and/or cure myopia and improve the visual acuity.
A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
The present invention provides a pharmaceutical composition, a method for preparing same, and use thereof. The pharmaceutical composition comprises a compound represented by formula I. The pharmaceutical composition of the present invention has high drug loading capacity, good uniformity, and good stability, and can be used for preparing a medicament for preventing and/or treating glaucoma or ocular hypertension.
A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
The present invention provides use of a steroid compound in preparing a product for preventing or treating skin pigmentation related conditions or anti-aging related products. The steroid compound is represented by formula I and has the effects of treating, desalting and relieving senile plaques, freckles, chloasma and the like caused by pigmentation on mammalian skin.
A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
Disclosed is a salt form of an isoquinolinone type compound as a ROCK protein kinase inhibitor and a preparation method therefor, and use of the salt form in the preparation of a medicament for treating glaucoma or ocular hypertension is further included.
Disclosed is a salt form of an isoquinolinone type compound as a ROCK protein kinase inhibitor and a preparation method therefor, and use of the salt form in the preparation of a medicament for treating glaucoma or ocular hypertension is further included.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
14.
USE OF STEROID COMPOUND IN PREPARING DRUGS FOR PREVENTING AND/OR TREATING PRESBYOPIA
The present invention provides use of a steroid compound in preparing drugs for preventing and/or treating presbyopia. The steroid compound provided by the present invention is represented by formula (I). The steroid compound has the effect of treating, alleviating and preventing presbyopia, and can greatly alleviate and/or cure presbyopia to improve vision.
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
A61P 27/10 - Ophthalmic agents for accommodation disorders, e.g. myopia
15.
APPLICATION OF STEROIDAL COMPOUND IN PREVENTION AND/OR TREATMENT OF CATARACTS
The present invention provides an application of a steroidal compound in the preparation of a drug for preventing and/or treating cataracts. The steroidal compound provided by the present invention can have good treatment, alleviation and prevention effects on cataracts, especially cortical cataract or mixed cataract that comprises the cortical cataract, can alleviate and/or cure the cortical cataract to a great extent, and improves the distant vision of a patient.
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
A steroidal compound, a preparation method therefor and an application thereof. On one hand, provided are a compound represented by formula I, a preparation method therefor, and an application thereof in a method for separating and purifying lanosterol; on the other hand, provided is the method for separating and purifying lanosterol. The method is simple to operate, stable in process, high in productivity and low in cost, and the obtained lanosterol has high purity and can meet medical application thereof.
C07J 9/00 - Normal steroids containing carbon, hydrogen, halogen, or oxygen, substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
patents
